Physician profile
Kris Houser
NPI 1992798284
$14,343.11
in general payments reported to CMS, 2019-2025
29 companies · $2,553 in 2025
The $2,553 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,862 · 2020: $919 · 2021: $1,311 · 2022: $1,819 · 2023: $3,566 · 2024: $2,313 · 2025: $2,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,432.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,619.82 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,127.43 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,685.82 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,632.50 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $986.73 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Lundbeck LLC | $821.29 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $758.34 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $606.48 | 2019-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $511.39 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $464.62 | 2019-2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $397.55 | 2022-2024 | Quviviq |
| Allergan, INC. | $306.93 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $254.41 | 2023-2024 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $229.26 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $136.87 | 2020-2025 | Trintellix |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $127.06 | 2019-2020 | |
| Bausch Health US, LLC | $115.08 | 2022-2023 | Aplenzin, Wellbutrin |
| Almatica Pharma LLC | $109.78 | 2022-2025 | Loreev Xr |
| Neuronetics, INC. | $102.27 | 2019-2021 | |
| Adlon Therapeutics L.P. | $79.91 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $64.68 | 2025 | Cobenfy |
| Tris Pharma INC | $54.85 | 2023-2025 | Dyanavel Xr |
| Arbor Pharmaceuticals, INC. | $42.69 | 2019-2020 | |
| Corium, LLC | $30.48 | 2023 | Azstarys |
| Jazz Pharmaceuticals INC. | $20.53 | 2022 | |
| Merck Sharp & Dohme LLC | $19.05 | 2022 | |
| Shire North American Group INC | $13.46 | 2019 | |
| Indivior INC. | $12.14 | 2019 | |
| Eisai INC. | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kris Houser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.